Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

KoalaFlipper Jun. 15 at 9:42 AM

$CGEN no news and people are selling.

0 · Reply

KoalaFlipper Jun. 11 at 2:36 PM

$OTLK Next bull 🐂🚀📈 runners!! might be $COCH Envoy Medical is a leader in hearing solutions. $NRSN NeuroSense Therapeutics is a late-stage clinical biotech company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. $CGEN From Code to Cure® Compugen is transforming the pathway to immuno-oncology therapeutics with Unigen™, a unique flexible-loop platform that integrates deep scientific knowledge and AI/ML innovation to pioneer novel targets and first-in-class drug. Remember doing you own research before buying any stock. Lets get rich!! 📈🚀🙏

0 · Reply

DARKP00L Jun. 11 at 12:13 PM

$CGEN 07:14 on Jun. 11 2026 Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026 #tradeideas

0 · Reply

KoalaFlipper Jun. 11 at 12:03 PM

$CGEN it falls you buy more 📈🚀

0 · Reply

TwitteringTom Jun. 10 at 8:28 PM

$CGEN oh nice a fireside chat ... cant wait for nothing to come about after

0 · Reply

John_McClane911 Jun. 9 at 4:44 PM

$CGEN

0 · Reply

TwitteringTom Jun. 9 at 3:31 PM

$CGEN lol suck suck suck and more suck

0 · Reply

KoalaFlipper Jun. 8 at 12:40 PM

$CGEN back to $2,40

0 · Reply

mary46 Jun. 4 at 10:44 PM

$CGEN then loader up

0 · Reply

mary46 Jun. 4 at 10:43 PM

$CGEN back to a 1.50

1 · Reply

Compugen Transcript: Fireside chat

Jun 11, 2026, 7:00 AM EDT - 4 days ago

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Jun 8, 2026, 7:00 AM EDT - 7 days ago

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

2026-05-21T10:11:15.000Z - 25 days ago

Compugen price target lowered to $5 from $13 at Leerink

May 19, 2026, 10:00 AM EDT - 27 days ago

Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum

2026-05-18T20:06:28.000Z - 4 weeks ago

Compugen files $400M mixed securities shelf

May 18, 2026, 8:30 AM EDT - 4 weeks ago

Compugen Earnings Call Transcript: Q1 2026

May 18, 2026, 8:30 AM EDT - 4 weeks ago

Compugen Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Compugen Registration statement: Registration filing

2026-05-18T11:05:06.000Z - 4 weeks ago

Compugen reports Q1 EPS (8c) vs. (8c) last year

May 18, 2026, 7:00 AM EDT - 4 weeks ago

Compugen Reports First Quarter 2026 Results

May 14, 2026, 7:00 AM EDT - 4 weeks ago

Compugen Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 4, 2026, 7:00 AM EDT - 6 weeks ago

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Apr 13, 2026, 8:45 AM EDT - 2 months ago

Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

2026-04-07T11:44:13.000Z - 2 months ago

Compugen initiated with a Buy at Lake Street

AZN GILD MRK

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Compugen Slides: Corporate presentation

Mar 9, 2026, 8:40 AM EDT - 3 months ago

Compugen Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:30 AM EST - 3 months ago

Compugen Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 3 months ago

Compugen Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 3 months ago

Compugen Earnings release: Q4 2025

2026-03-02T12:22:05.000Z - 3 months ago

Compugen reports Q4 EPS 60c vs. (7c) last year

Mar 2, 2026, 7:00 AM EST - 3 months ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 2:00 PM EST - 3 months ago

Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 4 months ago

Compugen to Participate in Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 4 months ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 12, 2026, 7:00 AM EST - 4 months ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Jan 11, 2026, 7:00 AM EST - 5 months ago

Compugen Slides: Corporate presentation

2026-01-07T11:10:47.000Z - 5 months ago

Compugen initiated with a Buy at H.C. Wainwright

2025-12-17T12:12:00.000Z - 6 months ago

Compugen and AstraZeneca agree to monetize rilvegostomig future royalties

AZN

Dec 17, 2025, 7:00 AM EST - 6 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Nov 11, 2025, 3:20 PM EST - 7 months ago

Compugen Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 7 months ago

Compugen Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Compugen Earnings release: Q3 2025

2025-11-10T12:23:25.000Z - 7 months ago

Compugen reports Q3 EPS (7c), consensus (9c)

Nov 10, 2025, 7:00 AM EST - 7 months ago

Compugen Reports Third Quarter 2025 Results

Nov 7, 2025, 7:00 AM EST - 7 months ago

Compugen Slides: Corporate presentation

Nov 4, 2025, 7:00 AM EST - 7 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present at SITC 2025

Sep 16, 2025, 11:30 AM EDT - 9 months ago

Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-07T11:35:33.000Z - 11 months ago

Compugen price target raised to $13 from $10 at Leerink

AZN

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Compugen Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Compugen Earnings release: Q2 2025

2025-08-06T11:26:38.000Z - 11 months ago

Compugen reports Q2 EPS (8c), consensus (9c)

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Compugen Reports Second Quarter 2025 Results

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Compugen Slides: Investor presentation

Jul 28, 2025, 7:00 AM EDT - 11 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 11 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

2025-07-21T11:05:54.000Z - 11 months ago

Compugen begins dosing in ovarian cancer trial

Jul 21, 2025, 7:00 AM EDT - 11 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q1 2025

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings release: Q1 2025

May 19, 2025, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2025 Results

May 16, 2025, 7:00 AM EDT - 1 year ago

Compugen Slides: Corporate presentation

2025-05-13T11:12:07.000Z - 1 year ago

Compugen appoints Eran Ophir as CEO, announces leadership transitions

May 13, 2025, 7:00 AM EDT - 1 year ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Apr 9, 2025, 12:00 PM EDT - 1 year ago

Compugen Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 9:30 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Compugen Slides: Corporate presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Annual report: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings release: Q4 2024

2025-03-04T12:06:24.000Z - 1 year ago

Compugen reports Q4 EPS (7c) vs. 11c last year

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Compugen Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

2025-01-13T13:01:57.000Z - 1 year ago

Compugen initiated with an Outperform at Oppenheimer

AZN GILD

Jan 12, 2025, 7:00 AM EST - 1 year ago

Compugen Slides: Corporate presentation

2025-01-08T12:25:57.000Z - 1 year ago

Compugen says first patient dosed in Phase 1 trial of COM503

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

2024-11-27T12:06:19.000Z - 1 year ago

Compugen announces USPTO grants new patent for use of COM902

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Slides: Corporate presentation

Nov 18, 2024, 8:35 AM EST - 1 year ago

Compugen Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports Second Quarter 2024 Results

Aug 5, 2024, 7:00 AM EDT - 2 years ago

Compugen Slides: Corporate presentation

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present at Upcoming Antibody Industrial Symposium

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Compugen Slides: Corporate presentation

May 30, 2024, 7:00 AM EDT - 2 years ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings Call Transcript: Q1 2024

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings release: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 2 years ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

KoalaFlipper Jun. 15 at 9:42 AM

$CGEN no news and people are selling.

0 · Reply

KoalaFlipper Jun. 11 at 2:36 PM

0 · Reply

DARKP00L Jun. 11 at 12:13 PM

$CGEN 07:14 on Jun. 11 2026 Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026 #tradeideas

0 · Reply

KoalaFlipper Jun. 11 at 12:03 PM

$CGEN it falls you buy more 📈🚀

0 · Reply

TwitteringTom Jun. 10 at 8:28 PM

$CGEN oh nice a fireside chat ... cant wait for nothing to come about after

0 · Reply

John_McClane911 Jun. 9 at 4:44 PM

$CGEN

0 · Reply

TwitteringTom Jun. 9 at 3:31 PM

$CGEN lol suck suck suck and more suck

0 · Reply

KoalaFlipper Jun. 8 at 12:40 PM

$CGEN back to $2,40

0 · Reply

mary46 Jun. 4 at 10:44 PM

$CGEN then loader up

0 · Reply

mary46 Jun. 4 at 10:43 PM

$CGEN back to a 1.50

1 · Reply

zerodayrounder Jun. 3 at 7:17 PM

$CGEN so that bull flag break out rejection from a month ago was the signal of what was to come.

0 · Reply

AGC_Trader Jun. 3 at 1:39 PM

$CGEN at this point, it's probably going to touch the 200EMA on the daily chart at $2.10. I hope for a strong support there...

0 · Reply

KoalaFlipper Jun. 2 at 9:48 PM

$CGEN looks like its getting heavy shorted.

1 · Reply

Gollum00 Jun. 2 at 7:31 PM

$CGEN WTF

0 · Reply

zerodayrounder Jun. 2 at 3:22 PM

$CGEN was market expecting something at ASCO? What happened here?

0 · Reply

Otus Jun. 2 at 2:05 PM

$CGEN started buying more today. 10k shares and I’ve just started. I’ll keep buying in this weakness. Been a low volume decline.

2 · Reply

TwitteringTom Jun. 2 at 1:35 PM

$CGEN

0 · Reply

zerodayrounder Jun. 1 at 5:34 PM

$CGEN pretty nasty price action here. I'm not following closely -- what is chances one of their Big Pharma partners takes them out? Doesn't $AZN have like 12 programs dependent on molecules licensed from CGEN?

0 · Reply

xale30x Jun. 1 at 3:07 PM

$CGEN

0 · Reply

TwitteringTom Jun. 1 at 1:56 PM

$CGEN fat dump city

0 · Reply

AngelosProject May. 27 at 5:10 PM

$CGEN secured my orders

0 · Reply

TwitteringTom May. 27 at 3:50 PM

$CGEN so the over 3$ per share was a mirage

1 · Reply

Market Cap	192.89M
Revenue (ttm)	72.76M
Net Income (ttm)	35.34M
EPS (ttm)	N/A
PE Ratio	5.51
Forward PE	N/A
Profit Margin	48.57%
Debt to Equity Ratio	0.00

Volume	288,500
Avg Vol	551,152
Day's Range	N/A - N/A
Shares Out	94.55M
Stochastic %K	19%
Beta	2.74
Analysts	Strong Sell
Price Target	$4.50